印度尼西亚国家癌症中心肺癌患者的基因组特征。
Genomic features of lung cancer patients in Indonesia's national cancer center.
机构信息
Department of Pulmonology, Dharmais Cancer Hospital, National Cancer Center, Letjen S. Parman Street Kav. 84-86 Slipi Jakarta Barat, DKI Jakarta, West Jakarta, 11420, Indonesia.
Department of Internal Medicine, Division of Hematology and Medical Oncology, Dharmais Cancer Hospital, National Cancer Center, West Jakarta, Indonesia.
出版信息
BMC Pulm Med. 2024 Jan 20;24(1):43. doi: 10.1186/s12890-024-02851-y.
INTRODUCTION
Advances in molecular biology bring advantages to lung cancer management. Moreover, high-throughput molecular tests are currently useful for revealing genetic variations among lung cancer patients. We investigated the genomics profile of the lung cancer patients at the National Cancer Centre of Indonesia.
METHODS
A retrospective study enrolled 627 tissue biopsy samples using real time polymerase chain reaction (RT-PCR) and 80 circulating tumour DNA (ctDNA) liquid biopsy samples using next-generation sequencing (NGS) from lung cancer patients admitted to the Dharmais Cancer Hospital from January 2018 to December 2022. Data were obtained from medical records. Data statistically analysed with p < 0.05 is considered significant.
RESULT
The EGFR test results revealed by RT-PCR were wild type (51.5%), single variant (38.8%), double variant (8.3%), and triple variant (1.4%), with 18.66% L85R, 18.22% Ex19del, and 11.08% L861Q variant. Liquid biopsy ctDNA using NGS showed only 2.5% EGFR wild type, 62.5% single variant and 35% co-variant, with EGFR/TP53 and EGFR/PIK3CA as the highest.
CONCLUSION
EGFR variants are the most found in our centre. Liquid biopsy with ctDNA using NGS examination could detect broad variants and co-variants that will influence the treatment planning.
简介
分子生物学的进步为肺癌管理带来了优势。此外，高通量分子检测目前可用于揭示肺癌患者之间的遗传变异。我们研究了印度尼西亚国家癌症中心的肺癌患者的基因组学特征。
方法
一项回顾性研究纳入了 2018 年 1 月至 2022 年 12 月期间在 Dharmais 癌症医院住院的肺癌患者的 627 份组织活检样本（使用实时聚合酶链反应 [RT-PCR]）和 80 份循环肿瘤 DNA（ctDNA）液体活检样本（使用下一代测序 [NGS]）。数据来自病历。使用 p < 0.05 的数据进行统计学分析被认为是显著的。
结果
通过 RT-PCR 显示的 EGFR 检测结果为野生型（51.5%）、单变体（38.8%）、双变体（8.3%）和三变体（1.4%），其中 L85R 占 18.66%，Ex19del 占 18.22%，L861Q 变体占 11.08%。使用 NGS 的液体活检 ctDNA 仅显示 2.5%的 EGFR 野生型，62.5%的单变体和 35%的共变体，其中 EGFR/TP53 和 EGFR/PIK3CA 最高。
结论
在我们中心，最常见的是 EGFR 变体。使用 NGS 检查的 ctDNA 液体活检可以检测到广泛的变体和共变体，这将影响治疗计划。
Zotero 插件